NCT02308280View on ClinicalTrials.gov

Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

September 27, 2018

Study Completion Date

September 27, 2023

Conditions
Multiple MyelomaHigh-Risk Cancer
Interventions
DRUG

Bortezomib following nonmyeloablative allogeneic transplant

Bortezomib 1,3 mg/m2 subcutaneously every 2 weeks for 1 year (26 injections) starting on day +120 from a non myeloablative sibling or 10/10 unrelated allogeneic transplantation

Trial Locations (1)

H1T 2M4

Hôpital Maisonneuve-Rosemont, Montreal

All Listed Sponsors
lead

Maisonneuve-Rosemont Hospital

OTHER

NCT02308280 - Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma Patients | Biotech Hunter | Biotech Hunter